- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03992664
Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. (EGFR)
Effectiveness of Educational Intervention for Patients That Receive Treatment With EGFRI
The main adverse reaction of EGFR seen in patients is rash. EGFR treated patients have a 24-95% incidence of rash depending on the type of treatment they receive. Skin toxicity may occur in more than 80% of patients treated with cetuximab.
If a severe rash (Grade 3 or 4) occurs, a dose reduction or discontinuation of treatment may be required. Also, infections are the main secondary side effect caused by the rash.
The aim of the study is through a randomized clinical trial feasibility study to investigate the effectiveness of an educational intervention in patients receiving EGFRI therapy.
It will be randomly selected which patients will belong to the intervention group and who in the control group. The type of program involves educational intervention.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
In recent years, EGFRI (Epidermal Growth Factor Receptor Inhibitor) have evolved as effective anti-cancer drugs. They are distinguished in monoclonal antibodies (cetuximab and panitumumab) and EGFR (TKIs) kinase inhibitors gefitinib, erlotinib and lapatinib, where they are used in the treatment of colon, rectal, head and neck, lung, pancreas and of breast.
According to studies, the usual treatment for the prevention and treatment of skin rash refers to the use of antibiotics such as doxycycline, tetracycline and cortisone products such as hydrocortisone. It is also recommended to use moisturizing cream.
The study of Carmine P. et al., 2011 mentions the need to investigate educational measures for the rash due to EGFR treatment.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Athienou
-
Larnaca, Athienou, Kypros, 7600
- Eleni Papoui
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients who take EGFR therapy for the first time.
- Classify at 0 or 1 according to WHO performance status.
Exclusion Criteria:
- Patients with previous exposure to EGFR treatment.
- People already suffering from rash.
- People already suffering with other dermatological problems, eg psoriasis.
- People already taking part in any other study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: EDUCATION
If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
|
The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects. The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks.
Andre navn:
|
Ingen inngripen: NON-INTERVENTION
The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.
Tidsramme: 4 weeks
|
Identify the degree of rash using the NCI-CTCAE criteria.
the degree of rash will compare in the experimental group (education) and in the non-experimental group (no education).
|
4 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Evaluation of the quality of life of all patients through the SF 36 questionnaire
Tidsramme: 4 weeks
|
The SF 36 questionnaire will be given to every patient from the first time of the meeting.
The questionnaire will be given every week.
|
4 weeks
|
Assessing the quality of life in relation to the rash through the QLQI questionnaire.
Tidsramme: 3 weeks
|
The QLQI questionnaire will be given in every patient from the second meeting because the questionnaire concerns questions about last week.
|
3 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: ANDREAS CHARALAMBOUS, PhD, Cyprus University of Technology
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0000-0001-5580-7256
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på EDUCATION
-
Tokat Gaziosmanpasa UniversityFullførtStigmatisering | Funksjonalitet | Kollegastøtte | Kroniske psykiske lidelser | Psykososial ferdighetstrening | InnsiktTyrkia
-
Thomas Jefferson UniversityRekrutteringProstata karsinomForente stater
-
Universidade Federal de Sao CarlosFullført
-
VA Office of Research and DevelopmentRekruttering
-
VA Office of Research and DevelopmentFullført
-
Lokman Hekim ÜniversitesiFullført
-
Bilecik Seyh Edebali UniversitesiFullførtBruk av Flipped Classroom-modellen med sykepleierstudenterTyrkia
-
Centers for Disease Control and PreventionFullførtHIV-infeksjoner | Hepatitt CForente stater
-
Summa Health SystemFullførtHjertefeilForente stater
-
Thomas Jefferson UniversityFullførtHematopoetisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForente stater